SCHEMBL6715273

SCHEMBL6715273

O=S(=O)(c1cccc2ccccc12)N1CCc2cc(OCc3ccccc3)ccc2C1c1ccc(OCCN2CCCC2)cc1

nearest known ligand 0.82

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 11/20 0.82
ESR2 Q92731 11/20 0.82
LTA4H P09960 1/20 0.49
HTT P42858 1/20 0.48
KCNH2 Q12809 2/20 0.47
MCHR1 Q99705 2/20 0.47
GRIN1 Q05586 1/20 0.46
GRIN2B Q13224 1/20 0.46
MMP1 P03956 1/20 0.44
MMP2 P08253 1/20 0.44
MMP7 P09237 1/20 0.44
MMP9 P14780 1/20 0.44
MMP12 P39900 1/20 0.44
MMP14 P50281 1/20 0.44
MMP15 P51511 1/20 0.44
MMP16 P51512 1/20 0.44
MMP26 Q9NRE1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715457 0.90 ESR1 (1.00) ESR1ESR2KCNH2
SCHEMBL6713309 0.88 ESR1 (0.82) ESR1ESR2LTA4HHTTKCNH2
SCHEMBL6715455 0.81 ESR1 (0.61) ESR1ESR2LTA4HHTTKCNH2
SCHEMBL6716254 0.79 ESR1 (1.00) ESR1ESR2KCNH2
SCHEMBL6715473 0.78 ESR1 (0.65) ESR1ESR2LTA4HHTTKCNH2
SCHEMBL6716529 0.78 ESR1 (0.78) ESR1ESR2KCNH2
SCHEMBL6716757 0.78 ESR1 (0.82) ESR1ESR2LTA4HHTTGRIN1
SCHEMBL6718570 0.77 ESR1 (0.63) ESR1ESR2LTA4HHTTGRIN1
SCHEMBL6713548 0.76 ESR1 (0.78) ESR1ESR2LTA4HHTTGRIN1
SCHEMBL6718642 0.76 ESR1 (0.78) ESR1ESR2LTA4HHTTKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040192685-A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists CAMERON KIMBERLY O (US) 2004-09-30 US disclosed
US-20030220494-A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists CAMERON KIMBERLY O (US) 2003-11-27 US disclosed
US-6608203-B2 Devoid of unwanted side effects PFIZER INC. 2003-08-19 US disclosed
US-20010039285-A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists CAMERON KIMBERLY O (US) 2001-11-08 US disclosed
EP-1113007-A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists PFIZER INC. (US) 2001-07-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039285-A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists GPER1, ESR1, ESR2 ESR1 2/4885ESR2 3/4885LTA4H 973/4885
US-20030220494-A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists GPER1, ESR1, ESR2 ESR1 2/4885ESR2 3/4885LTA4H 973/4885
US-20040192685-A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists GPER1, ESR1, ESR2 ESR1 2/4885ESR2 3/4885LTA4H 973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.